Extracellular Vesicular Analysis of Glypican 1 mRNA and Protein for Pancreatic Cancer Diagnosis and Prognosis.
Hong LiChi-Ling ChiangKwang Joo KwakXinyu WangSital DoddiLakshmi V RamanathanSun M ChoYa-Chin HouTai-Shan ChengXiaokui MoYueh-Shih ChangHui-Lan ChangWeiming ChengWei-Ni TsaiLuong T H NguyenJunjie PanYifan MaXilal Y RimaJingjing ZhangEduardo ReateguiYeh-Shiu ChuPeter Mu-Hsin ChangPei-Hung ChangChi-Ying F HuangCheng-Hsu WangYan-Shen ShanChung-Pin LiMartin FleisherLy James LeePublished in: Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2024)
Detecting pancreatic duct adenocarcinoma (PDAC) in its early stages and predicting late-stage patient prognosis undergoing chemotherapy is challenging. This work shows that the activation of specific oncogenes leads to elevated expression of mRNAs and their corresponding proteins in extracellular vesicles (EVs) circulating in blood. Utilizing an immune lipoplex nanoparticle (ILN) biochip assay, these findings demonstrate that glypican 1 (GPC1) mRNA expression in the exosomes-rich (Exo) EV subpopulation and GPC1 membrane protein (mProtein) expression in the microvesicles-rich (MV) EV subpopulation, particularly the tumor associated microvesicles (tMV), served as a viable biomarker for PDAC. A combined analysis effectively discriminated early-stage PDAC patients from benign pancreatic diseases and healthy donors in sizable clinical from multiple hospitals. Furthermore, among late-stage PDAC patients undergoing chemotherapy, lower GPC1 tMV-mProtein and Exo-mRNA expression before treatment correlated significantly with prolonged overall survival. These findings underscore the potential of vesicular GPC1 expression for early PDAC screenings and chemotherapy prognosis.
Keyphrases
- poor prognosis
- locally advanced
- early stage
- binding protein
- patients undergoing
- end stage renal disease
- healthcare
- squamous cell carcinoma
- newly diagnosed
- chronic kidney disease
- long non coding rna
- stem cells
- mesenchymal stem cells
- peritoneal dialysis
- case report
- rectal cancer
- risk assessment
- neoadjuvant chemotherapy
- patient reported outcomes
- lymph node
- sentinel lymph node
- replacement therapy
- combination therapy